title: Osimertinib (AZD9291)-a science-driven, collaborative approach to rapid drug design and development.
authors.affiliation: Global Medicines Development, AstraZeneca, Cambridge, UK. Electronic address: antoine.yver@astrazeneca.com.
authors.forename: A
authors.initials: A
authors.lastname: Yver
mesh_terms: D000178:Acrylamides; D000814:Aniline Compounds; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D003299:Cooperative Behavior; D017277:Drug Approval / Q000379:methods; D015195:Drug Design; D055808:Drug Discovery / Q000379:methods* / Q000639:trends; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D010879:Piperazines / Q000737:chemistry / Q000627:therapeutic use*; D013997:Time Factors; D007211:Indoles; D011743:Pyrimidines
chemical_list: D000178:Acrylamides; D000814:Aniline Compounds; D000970:Antineoplastic Agents; D010879:Piperazines; C000596361:osimertinib; D007211:Indoles; D011743:Pyrimidines